3D Bioprinting Market by Component (3D bioprinters (Microextrusion, Inkjet, Laser), Bioinks, Software, Consumable), Material (Hydrogels, ECM), Application(Research (Regenerative Medicine, 3D cell Culture), Clinical (Skin, Bone)) - Global Forecast to 2029

3D Bioprinting Market by Component (3D bioprinters (Microextrusion, Inkjet, Laser), Bioinks, Software, Consumable), Material (Hydrogels, ECM), Application(Research (Regenerative Medicine, 3D cell Culture), Clinical (Skin, Bone)) - Global Forecast to 2029

The 3D bioprinting market is projected to reach USD 2.4 Billion by 2029 from USD 1.3 Billion in 2024, at a CAGR of 12.7% during the forecast period. The 3D bioprinting market is driven by several key factors, including increasing collaborations between public and private entities and significant investments in research and development and growing interest in regenerative medicine and stem cell research.

“The 3D bioprinters segment held the dominant share in the 3D bioprinting market.”

Based on technology, the global 3D bioprinting market is segmented into 3D bioprinters, bioinks, software, and consumable. The 3D bioprinters is segmented into Microextrusion bioprinters, , inkjet 3D bioprinters, laser-assisted bioprinters, magnetic 3D bioprinters, stereolithography-based bioprinters, and other 3D bioprinters. The 3D bioprinters segment dominated the 3D bioprinting market in 2023. Advancements in 3D bioprinting technology and rising demand for organ transplants serves as driving factor in the 3D bioprinting market.

“Research application accounted for the largest share of the application in 2023.”

Based on application, the 3D bioprinting market is segmented into research application and clinical application. The research application is further segmented into regenerative medicine, 3D cell culture and drug research Also, the clinical application is segmented into bone & cartilage, blood vessels, skin and other clinical applications. In 2023, Research segment dominated the 3D bioprinting market. Research segment is anticipated to grow at significant CAGR during the forecast period of 2024-2028 owing to various factors such as biopharmaceuticals firms ramping up their utilization of 3D bioprinting technology.

“Asia Pacific region is likely to grow at a faster pace in the 3D bioprinting market.”

The 3D bioprinting market region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. The Asia-Pacific region is poised to experience significant growth in the 3D bioprinting market due to several key factors such as increasing healthcare expenditure in countries like China, India, and Southeast Asian nations region benefits from a significant population base and domestic system manufacturing, driving increased partnerships and collaborations aimed at healthcare improvement. With a high level of R&D intensity, market players are actively expanding their presence in the region, complemented by a surge in stem cell research, further stimulate market growth.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70%, and Demand Side - 30%

By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%

By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, Middle East-and Africa -5%

List of Companies Profiled in the Report:

BICO Group AB (Sweden)

3D Systems Inc. (US)

Merck KGaA (Germany)

Organovo Holdings Inc (US)

Collplant Biotechnologies Ltd. (Israel)

regenHU (Switzerland)

Aspect Biosystem Ltd. (Canada)

Advanced Solutions Life Sciences, llc (US)

Cyfuse Biomedical K.K (Japan)

Rokit Healthcare Inc (South Korea)

Hangzhou Genofei Biotechnology Co., Ltd. (China)

Foldink (Armenia)

Brinter (US)

3D bioprinting solution (Russia).

REGEMAT 3D, SL (Spain)

Ροietis (France)

Sunp Biotech (US)

GeSim – Gesellschaft Für Silizium-Mikrosysteme Mbh (Germany)

Medprin (China)

Voxcell Bioinnovation Inc. (Canada)

Prodways (France)

Inventia Life Science Pty Ltd (Australia)

Upnano Gmbh (Austria)

UPM (Finland)

Tissuelabs (Switzerland)

Research Coverage:

This report provides a detailed picture of the vaccine market. It aims at estimating the size and future growth potential of the market across different segments such as the components, material, application, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall 3D bioprinting market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (growing adoption of 3D bioprinting technology in the pharmaceutical and cosmetic industries, technological advancement in the 3D bioprinting , increasing number of public-private partnerships, rising investments in R&D and medical devices), opportunities (Rising demand for organ transplants and growing demand for regenerative medicine and stem cell research) and challenges (biocompatibility issues and rigorous sterilization protocols and ethical concerns related to the use of 3D bioprinted products) are influencing the growth of 3D bioprinting market.

Product Development/Innovation: Detailed insights on newly launched products of the 3D bioprinting market.

Market Development: Comprehensive information about lucrative markets – the report analyses the 3D bioprinting market across varied regions.

Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the 3D bioprinting market..

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include BICO Group AB (Sweden), 3D Systems Inc. (US), Merck KGaA (Germany), Organovo Holdings Inc (US), Collplant Biotechnologies Ltd (Israel), regenHU (Switzerland), Aspect Biosystem (Canada), Advanced Solutions Life Sciences, llc (US), Cyfuse Biomedical K.K (Japan), Rokit Healthcare (South Korea), Hangzhou Genofei Biotechnology Co., Ltd. (China), Foldink (Armenia), Brinter (US) and 3D bioprinting solution (Russia).